NTRK1

(redirected from Tyrosine Kinase Receptor)
Also found in: Acronyms.

NTRK1

A gene on chromosome 1q21-q22 that encodes neurotrophic tyrosine kinase receptor type 1 (TrkA) which, after neurotrophin binding, phosphorylates itself (autophosphorylates) and members of the MAPK pathway. TrkA potently binds nerve growth factor (NGF) and is involved in differentiation and survival of neurons and in control of gene expression of enzymes involved in neurotransmitter synthesis. It is involved in cell differentiation and may play a role in specifying sensory neuron subtypes.

Molecular pathology
NTRK1 mutations are associated with congenital insensitivity to pain with anhidrosis, self-mutilating behaviour, mental retardation and cancer.
References in periodicals archive ?
The PI3K/Akt pathway is a downstream target of the EGFR family and other tyrosine kinase receptors.
EGFR (also called erbB1) is the first member of a closely related group of tyrosine kinase receptors known as the erbB family, the remaining three being erbB2, erbB3 and erbB4.
CT-322 is a mono-specific blocker of the tyrosine kinase receptor, VEGFR-2, and blocks its activation by all known extracellular ligands; VEGF-A, VEGF-C, and VEGF-D.
This announcement contains, in addition to historical information, certain "forward-looking statements" regarding the development of a novel BiTE(R) molecule (bscEphA2xCD3) targeting the tyrosine kinase receptor EphA2 to treat certain cancers.
These include inhibitors of aurora-A kinase and products which target the tyrosine kinase receptor family.
The study, entitled "FGFR4 G388R mutation, but not FGFR4 or HER2 overexpression, correlates with survival in head and neck squamous cell carcinoma (HNSCC) patients," examined the correlation between survival and two variations (or SNPs) in FGFR4 compared with the expression of FGFR4 and HER2, another tyrosine kinase receptor.
Anti-flk-1 is a monoclonal antibody that blocks a key tyrosine kinase receptor, FLK-1/KDR, located on tumor-associated vascular endothelial cells.
The data further demonstrated that DC101 blocks a key tyrosine kinase receptor (FLK-1/KDR) located on the tumor associated vascular endothelial cells.
The data further demonstrated that DC101, a monoclonal antibody developed by ImClone, blocks a key tyrosine kinase receptor (FLK-1/KDR) located on the tumor associated vascular endothelial cells.
These include antiangiogenic agents, immunotherapy, bacterial agents, viral oncolysis, targeting of cyclic-dependent kinases and tyrosine kinase receptors, antisense approaches, gene therapy and combination of various methods.
So far, most of the drugs for lung cancer that have been approved, are pending approval, or are under investigation target tyrosine kinase receptors or their ligands.
Our current perception is that metformin may constitute a novel "hybrid anti-cancer pill" physically combining both the long-lasting effects of antibodies-by persistently lowering levels of blood insulin and glucose-and the immediate potency of a cancer cell-targeting molecular agent-by suppressing the pivotal AMPK/mTOR/S6K1 axis and several protein kinases at once, including tyrosine kinase receptors such as HER1 and HER2-.

Full browser ?